263 related articles for article (PubMed ID: 25502494)
21. LONGITUDINAL CHANGES IN EYES WITH HYDROXYCHLOROQUINE RETINAL TOXICITY.
Allahdina AM; Chen KG; Alvarez JA; Wong WT; Chew EY; Cukras CA
Retina; 2019 Mar; 39(3):473-484. PubMed ID: 30741731
[TBL] [Abstract][Full Text] [Related]
22. Fluorescence Lifetimes in Patients With Hydroxychloroquine Retinopathy.
Solberg Y; Dysli C; Möller B; Wolf S; Zinkernagel MS
Invest Ophthalmol Vis Sci; 2019 May; 60(6):2165-2172. PubMed ID: 31108547
[TBL] [Abstract][Full Text] [Related]
23. Abnormal multifocal ERG findings in patients with normal-appearing retinal anatomy.
Talamini CL; Raza AS; Dale EA; Greenstein VC; Odel JG; Hood DC
Doc Ophthalmol; 2011 Dec; 123(3):187-92. PubMed ID: 22045265
[TBL] [Abstract][Full Text] [Related]
24. Microperimetric sensitivity in patients on hydroxychloroquine (Plaquenil) therapy.
Jivrajka RV; Genead MA; McAnany JJ; Chow CC; Mieler WF
Eye (Lond); 2013 Sep; 27(9):1044-52. PubMed ID: 23764990
[TBL] [Abstract][Full Text] [Related]
25. Case Report: Hydroxychloroquine Retinopathy.
Eldeeb M; Chan EW; Omar A
Optom Vis Sci; 2018 Jun; 95(6):545-549. PubMed ID: 29787487
[TBL] [Abstract][Full Text] [Related]
26. Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss.
Stepien KE; Han DP; Schell J; Godara P; Rha J; Carroll J
Trans Am Ophthalmol Soc; 2009 Dec; 107():28-33. PubMed ID: 20126479
[TBL] [Abstract][Full Text] [Related]
27. Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease.
Navajas EV; Krema H; Hammoudi DS; Lipton JH; Simpson ER; Boyd S; Easterbrook M
Can J Ophthalmol; 2015 Dec; 50(6):442-50. PubMed ID: 26651304
[TBL] [Abstract][Full Text] [Related]
28. Early hydroxychloroquine retinopathy: optical coherence tomography abnormalities preceding Humphrey visual field defects.
Garrity ST; Jung JY; Zambrowski O; Pichi F; Su D; Arya M; Waheed NK; Duker JS; Chetrit Y; Miserocchi E; Giuffrè C; Kaden TR; Querques G; Souied EH; Freund KB; Sarraf D
Br J Ophthalmol; 2019 Nov; 103(11):1600-1604. PubMed ID: 30819690
[TBL] [Abstract][Full Text] [Related]
29. A novel method for screening the multifocal electroretonogram in patients using hydroxychloroquine.
Chang WH; Katz BJ; Warner JE; Vitale AT; Creel D; Digre KB
Retina; 2008; 28(10):1478-86. PubMed ID: 18997610
[TBL] [Abstract][Full Text] [Related]
30. En Face Optical Coherence Tomography Imaging of the Photoreceptor Layers in Hydroxychloroquine Retinopathy.
Ahn SJ; Joung J; Lee BR
Am J Ophthalmol; 2019 Mar; 199():71-81. PubMed ID: 30448463
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Progression of Pericentral Hydroxychloroquine Retinopathy.
Ahn SJ; Seo EJ; Kim KE; Kim YJ; Lee BR; Kim JG; Yoon YH; Lee JY
Ophthalmology; 2021 Jun; 128(6):889-898. PubMed ID: 33129843
[TBL] [Abstract][Full Text] [Related]
32. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine.
Kellner U; Renner AB; Tillack H
Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3531-8. PubMed ID: 16877425
[TBL] [Abstract][Full Text] [Related]
33. Night Blindness, Ring Scotoma, and a Nonrecordable Electroretinogram in an Elderly Woman.
Grassi MA; Maker MP; Marmor MF
JAMA Ophthalmol; 2019 Jan; 137(1):109-110. PubMed ID: 30452517
[No Abstract] [Full Text] [Related]
34. Visual Field Sensitivity Prediction Using Optical Coherence Tomography Analysis in Hydroxychloroquine Toxicity.
Jayakar G; De Silva T; Cukras CA
Invest Ophthalmol Vis Sci; 2022 Jan; 63(1):15. PubMed ID: 35015028
[TBL] [Abstract][Full Text] [Related]
35. Effect of disease stage on progression of hydroxychloroquine retinopathy.
Marmor MF; Hu J
JAMA Ophthalmol; 2014 Sep; 132(9):1105-12. PubMed ID: 24922444
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Hydroxychloroquine Retinopathy Using Ultra-Widefield Fundus Autofluorescence: Peripheral Findings in the Retinopathy.
Ahn SJ; Joung J; Lee BR
Am J Ophthalmol; 2020 Jan; 209():35-44. PubMed ID: 31526798
[TBL] [Abstract][Full Text] [Related]
37. Value of red targets and pattern deviation plots in visual field screening for hydroxychloroquine retinopathy.
Marmor MF; Chien FY; Johnson MW
JAMA Ophthalmol; 2013 Apr; 131(4):476-80. PubMed ID: 23710501
[TBL] [Abstract][Full Text] [Related]
38. Hydroxychloroquine screening practice patterns within a large multispecialty ophthalmic practice.
Au A; Parikh V; Modi YS; Ehlers JP; Schachat AP; Singh RP
Am J Ophthalmol; 2015 Sep; 160(3):561-568.e2. PubMed ID: 26116260
[TBL] [Abstract][Full Text] [Related]
39. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.
Marmor MF; Kellner U; Lai TY; Lyons JS; Mieler WF;
Ophthalmology; 2011 Feb; 118(2):415-22. PubMed ID: 21292109
[TBL] [Abstract][Full Text] [Related]
40. Perifoveal interdigitation zone loss in hydroxychloroquine toxicity leads to subclinical bull's eye lesion appearance on near-infrared reflectance imaging.
Chew AL; Sampson DM; Chelva E; Khan JC; Chen FK
Doc Ophthalmol; 2018 Feb; 136(1):57-68. PubMed ID: 29124422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
